Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fasting Conditions

NCT01712139 is registered in ClinicalTrials.gov with Roxane Laboratories as lead sponsor.

NCT NCT01712139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fasting Conditions
Lead sponsor
Roxane Laboratories
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2007
Completion date
September 30, 2007
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension